Immunoepigenetics: The unseen side of cancer immunoediting

Immunology and Cell Biology

Volumn 85, Issue 1, 2007, Pages 55-59

  Germenis, A E ^a   Karanikas, V ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

DNA methylation; Epigenetic drugs; Immune escape; Immunoediting; Immunoepigenetics; Immunosurveillance

Indexed keywords

ALLELE; ARTICLE; CANCER CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; DNA METHYLATION; DNA POLYMORPHISM; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE FUNCTION; GENE LOCUS; HOST; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENCE; IMMUNOGENETICS; IMMUNOGENICITY; IMMUNOSURVEILLANCE; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; PHENOTYPE; RNA EDITING; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR RESISTANCE;

ANTIGENS, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; NEOPLASMS;

EID: 33846089959     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100006     Document Type: Article

References (74)

1. Davis ID, Jefford M, Parente P, Cebon J. Rationale approaches to human cancer immunotherapy. J Leuk Biol 2003; 73: 3-29.
2. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004; 10: 887-892.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-913.
4. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004; 95: 697-703.
5. Palucka AK, Laupeze B, Aspord C, Saito H, Jego G, Fay J et al. Immunotherapy via dendritic cells. Adv Exp Med Biol 2005; 560: 105-114.
6. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8: 271-280.
7. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114: 1209-1217.
8. Woodland DL, Dutton RW. Heterogeneity of CD4+ and CD8+ T cells. Curr Opin Immunol 2003; 15: 336-342.
9. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005; 17: 326-332.
10. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Curr Opin Immunol 2005; 17: 320-325.
11. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-299.
12. Ochsenbein AF. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther 2002; 9: 1043-1055.
13. Pawelec G. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 2004; 53: 262-274.
14. Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996; 26: 1844-1850.
15. Engel AM, Svane IM, Rygaard J, Werdelin O. MCA sarcomas induced in Scid mice are more immunogenic than MCA sarcomas induced in congenic immunocompetent mice. Scand J Immunol 1997; 45: 463-470.
16. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
17. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649.
18. Rees RC, Mian S. Selective MHC expression in tumours modulates adaptive and innate antitumour responses. Cancer Immunol Immunother 1999; 48: 374-381.
19. Smyth MJ. Type I interferon and cancer immunoediting. Nat Immunol 2005; 7: 646-648.
20. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998.
21. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360.
22. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148.
23. Schreiber RD. Cancer Vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immunity 2005; 5 (Suppl 1): 1-8.
24. Dunn GP, Bruce AT, Sheehan KCF, Shankaran V, Uppaluri R, Bui JD et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6: 722-729.
25. Jin P, Wang E. Polymorphism in clinical immunology - from HLA typing to immunogenetic profiling. J Translation Med 2003; 1: 8.
26. Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 2004; 53: 1146-1152.
27. Whiteside TL. Down-regulation of ζ-chain expression in T-cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004; 53: 865-878.
28. Blanck G. Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunol Immunother 2004; 53: 1-16.
29. Teitell M, Richardson B. DNA methylation in the immune system. Clin Immunol 2003; 109: 2-5.
30. Fitzpatrick DR, Wilson CB. Methylation and demethylation in the regulation of genes, cells, and responses in the immune system. Clin Immunol 2003; 109: 37-45.
31. Reiner SL. Epigenetic control in the immune response. Hum Mol Genet 2005; 14: R41-R46.
32. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-153.
33. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 14: R65-R76.
34. Jones PA. Overview of cancer epigenetics. Semin Hematol 2005; 42: S3-S8.
35. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005; 26: 1481-1487.
36. Smale ST, Fisher AG. Chromatin structure and gene regulation in the immune system. Annu Rev Immunol 2002; 20: 427-462.
37. Woodson K, Mason J, Choi SW, Hartman T, Tangrea J, Virtamo J et al. Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 69-74.
38. Russo AL, Thiagalingam A, Pan H, Califano J, Cheng KH, Ponte JF et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 2005; 11: 2466-2470.
39. Walker PR, Calzascia T, Schnuriger V, Chalmers D, Saas P, Dietrich P-Y. Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation. Cell Immunol 2000; 206: 51-58.
40. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001; 60: 433-440.
41. Tan EM, Shi F-D. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol 2003; 134: 169-177.
42. Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy - is there an association? Scand J Rheumatol 2001; 30: 185-188.
43. Ramos-Casals M, Brito-Zerón P, López-Soto A, Font J. Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia. Autoimmun Rev 2004; 3: 376-382.
44. Richardson B. DNA methylation and autoimmune disease. Clin Immunol 2003; 109: 72-79.
45. Januchowski R, Prokop J, Jagodzinski PP. Role of epigenetic DNA alterations in the pathogenesis of systemic lupus erythematosus. J Appl Genet 2004; 45: 237-248.
46. Richardson BC. Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 2002; 132: 2401S-2405S.
47. Jiang Y, Bressler J, Beaudet AL. Epigenetics and human diseases. Ann Rev Hum Genet 2004; 5: 479-510.
48. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 2003; 5: 46-62.
49. Nardone G, Rocco A, Malfertheiner P. Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment Pharmacol Ther 2004; 20: 261-270.
50. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61: 3573-3577.
51. Gonzalgo ML, Issacs WB. Molecular pathways to prostate cancer. J Urol 2003; 170: 2444-2452.
52. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005; 96: 206-211.
53. Rahman I. Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: antioxidant therapeutic targets. Curr Drug Targets Inflamm Allergy 2002; 1: 291-315.
54. Liu C, Xu D, Sjöberg J, Forsell P, Björkholm M, Cleasson H-E. Transcriptional regulation of 15-lipoxygenase expression by promoter methylation. Exp Cell Res 2004; 297: 61-67.
55. Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene 2002; 21: 5388-5393.
56. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293: 1068-1070.
57. Doerfler W. Uptake of foreign DNA by mammalian cells via the gastrointestinal tract in mice: methylation of foreign DNA - a cellular defense mechanism. Curr Top Microbiol Immunol 1995; 197: 209-224.
58. Muller K, Heller H, Doerfler W. Foreign DNA integration. Genome-wide perturbations of methylation and transcription in the recipient genomes. J Mol Biol 2001; 276: 14271-14278.
59. Osawa T, Chong JM, Sudo M, Sakuma K, Uozaki H, Shibahara J et al. Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma. Jpn J Cancer Res 2002; 93: 1195-1200.
60. Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG et al. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002; 160: 787-794.
61. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000; 32: 970-979.
62. Matsukura S, Soejima H, Nakagawachi T, Yakushiji H, Ogawa A, Fukuhara M et al. CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer 2003; 88: 521-529.
63. Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T et al. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004; 64: 6002-6009.
64. Asano Y, Maeda M, Uchida N, Yokoyama T, Osaki K, Shimoda K et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 2001; 80: 634-638.
65. Sugimori C, Kaito K, Nakao S. Persistent remission after immunosuppressive therapy of hairy cell leukemia mimicking aplastic anemia: two case reports. Int J Hematol 2003; 77: 391-394.
66. Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer 2004; 100: 441-454.
67. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-463.
68. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003; 4: 351-358.
69. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
70. Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 2003; 22: 4118-4127.
71. Carbone M, Klein G, Gruber J, Wong M. Modern criteria to establish human cancer etiology. Cancer Res 2004; 64: 5518-5524.
72. Pöschl G, Stickel F, Wang XD, Seitz HK. Alcohol and cancer: genetic and nutritional aspects. Proc Nutr Soc 2004; 63: 65-71.
73. Hammons GJ, Yan Y, Lopatina NG, Jin B, Wise C, Blann EB et al. Increased expression of hepatic DNA methyltransferase in smokers. Cell Biol Toxicol 1999; 15: 389-394.
74. Vercelli D. Genetics, epigenetics, and the environment: switching, buffering, releasing. J Allergy Clin Immunol 2004; 113: 381-386.